Llwytho...
Oligonucleotide therapeutics in neurodegenerative diseases
Therapeutics that directly target RNAs are promising for a broad spectrum of disorders, including the neurodegenerative diseases. This is exemplified by the FDA approval of Nusinersen, an antisense oligonucleotide (ASO) therapeutic for spinal muscular atrophy (SMA). RNA targeting therapeutics are cu...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | RNA Biol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6152438/ https://ncbi.nlm.nih.gov/pubmed/29560813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15476286.2018.1454812 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|